Marginal Zone Lymphoma


Find out if you qualify

Image Description

The CITADEL-204 and 205 study is testing an investigational drug. This means the drug is not approved by the US Food and Drug Administration (FDA) for use in relapsed or refractory marginal zone lymphoma (MZL).

Treatment process

During the study, you may undergo the following:

You will need to get a complete physical exam to see if you are eligible for the study. During that screening, you will need to

Give blood samples

Have an electrocardiogram (ECG), a test that checks the condition of your heart

Have a computed tomography (CT) or magnetic resonance imaging (MRI) scan

Have a tumor biopsy and a bone marrow biopsy if you have not had them recently


The study drug will be provided at no cost to you. The study team may help you check with your health plan and your doctor about any costs related to the study. Your routine medical care will be billed to you or your insurer in the ordinary manner. You will not be paid for being in the study.

Join a study

Interested to enroll in a study?

See if you qualify today

All fields marked with * are mandatory